PTC Therapeutics (PTCT)
NASDAQ:PTCT
Want to see PTCT full AI Analyst Report?
Top Page
PTC Therapeutics
(NASDAQ:PTCT)
Select Model
Select Model
Rating:56Neutral
Price Target:
$73.00
▲(0.79% Upside)
Action:Reiterated
Date:06/06/26
PTCT scores as neutral overall: a strong, guidance-raising earnings narrative and Sephience launch execution support the outlook, but this is tempered by weak/volatile financial statement quality (TTM losses and cash burn, negative equity) and limited valuation support from a negative P/E. Technicals are broadly neutral, consistent with a stock consolidating near major moving averages.
Positive Factors
Sephience commercial launch momentum
Sustained prescription growth, strong refill rates and broadening payer coverage indicate durable commercial adoption. The steady cadence of new starts and planned multi-country rollout support multi-period revenue scaling, improving predictability of product-led cash flow and market penetration.
Negative Factors
Negative stockholders’ equity and leverage risk
Persistent negative equity and meaningful debt complicate capital allocation and raise refinancing and covenant risks. Negative equity distorts returns metrics, can limit access to unsecured financing, and reduces balance‑sheet flexibility for sustained investment or corrective M&A over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Sephience commercial launch momentum
Sustained prescription growth, strong refill rates and broadening payer coverage indicate durable commercial adoption. The steady cadence of new starts and planned multi-country rollout support multi-period revenue scaling, improving predictability of product-led cash flow and market penetration.
Read all positive factors
PTC Therapeutics Key Performance Indicators (KPIs)
Any
Revenue by Product
Shows how much revenue each product generates, highlighting which products are driving growth and which may need strategic adjustments.
Shows how much revenue each product generates, highlighting which products are driving growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyPTC Therapeutics (PTCT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.86B
Dividend YieldN/A
Average Volume (3M)1.39M
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue Growth-53.34%
EPS Growth-130.87%
CountryUS
Employees939
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.33
Shares Outstanding82,949,340
10 Day Avg. Volume1,074,827
30 Day Avg. Volume1,386,850
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-29.43
Price to Sales (P/S)3.49
P/FCF Ratio8.60
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue6.88
Enterprise Value/Gross Profit8.83
Enterprise Value/Ebitda-256.42
Forecast
1Y Price Target
$94.00Price Target Upside29.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.56
Revenue Forecast (FY)$1.15B
PTC Therapeutics Business Overview & Revenue Model
Company Description
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various s...
How the Company Makes Money
PTC Therapeutics makes money primarily through (1) net product sales of its commercial therapies in markets where it has commercialization rights, and (2) collaboration-related revenue from strategic partnerships. Product revenue is generated by s...
PTC Therapeutics Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call emphasized strong commercial execution and materially positive topline results driven by Sephience (record product revenue, 36% QoQ Sephience growth, raised 2026 guidance), meaningful clinical progress in Huntington's (votoplam) and a defined regulatory plan for vatiquinone — all supported by a healthy balance sheet. Lowlights were largely operational or timing issues in mature products (one‑time Translarna order, Emflaza generic erosion), a modest quarter‑to‑quarter cash decline, and the need for an additional vatiquinone trial which delays NDA plans. Overall, the positives (robust launch, guidance raise, favorable HD data, pipeline momentum) substantially outweigh the manageable challenges.Positive Updates
Record Quarterly Revenue and Strong YoY Growth
Total revenue of $273.0M and total product revenue of $226.0M in Q1 2026, representing a 47% increase in product revenue versus Q1 2025 (Q1 2025 product revenue $153M).
Negative Updates
Mature DMD Franchise Uncertainty and One‑Time Order Impact
DMD franchise revenue totaled $81M in Q1 2026, with Translarna contributing $59M that included a large one‑time government purchase order — indicating some near‑term revenue is non‑recurring and future Translarna demand is unpredictable.
Read all updates
Q1-2026 Updates
Positive
Negative
Record Quarterly Revenue and Strong YoY Growth
Total revenue of $273.0M and total product revenue of $226.0M in Q1 2026, representing a 47% increase in product revenue versus Q1 2025 (Q1 2025 product revenue $153M).
Read all positive updates
Company Guidance
PTC raised 2026 full‑year product revenue guidance to $750–$850 million and now expects total revenue of $1.08–1.18 billion, reflecting a record Q1 with total revenue of $273 million and net product revenue of $226 million (Sephience $125 million, up 36% quarter‑over‑quarter — U.S. $112M, international $13M); management reported 1,244 commercial Sephience patients as of March 31, over 2,200 prescriptions since launch, U.S. prescription starts averaging ~140/month and surpassing 1,500 starts in the quarter, plans for commercial sales in up to 30 countries by year‑end, strong refill rates with low double‑digit discontinuations, Q1 non‑GAAP R&D of $90M and non‑GAAP SG&A of $74M, cash and marketable securities of $1.89B, and reiterated confidence that Sephience can be a multi‑billion (>$2B) global opportunity.PTC Therapeutics Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
26
Negative
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 827.11M | 1.73B | 806.78M | 937.82M | 698.80M | 538.59M |
| Gross Profit | 643.84M | 1.66B | 749.38M | 872.34M | 654.12M | 506.26M |
| EBITDA | -22.18M | 887.66M | -120.46M | -330.34M | -367.78M | -368.18M |
| Net Income | -186.73M | 682.64M | -363.30M | -626.60M | -559.02M | -523.90M |
Balance Sheet | ||||||
| Total Assets | 2.87B | 2.91B | 1.71B | 1.90B | 1.71B | 1.94B |
| Cash, Cash Equivalents and Short-Term Investments | 1.89B | 1.95B | 1.14B | 876.74M | 410.70M | 773.38M |
| Total Debt | 395.09M | 492.28M | 2.47B | 2.23B | 1.46B | 1.27B |
| Total Liabilities | 3.05B | 3.12B | 2.80B | 2.71B | 2.05B | 1.94B |
| Stockholders Equity | -180.47M | -205.31M | -1.10B | -818.55M | -347.09M | 1.44M |
Cash Flow | ||||||
| Free Cash Flow | -228.96M | 702.34M | -181.94M | -279.04M | -509.11M | -336.66M |
| Operating Cash Flow | -217.95M | 711.20M | -107.69M | -158.42M | -356.65M | -251.33M |
| Investing Cash Flow | -771.36M | -861.98M | 44.18M | -176.74M | 290.18M | 219.18M |
| Financing Cash Flow | 328.09M | 331.09M | 255.87M | 646.40M | 167.95M | 20.88M |
PTC Therapeutics Technical Analysis
Positive
72.43
Price Trends
69.78
Positive
70.02
Positive
69.15
Positive
Market Momentum
0.26
Positive
51.66
Neutral
42.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PTCT, the sentiment is Positive. The current price of 72.43 is above the 20-day moving average (MA) of 71.44, above the 50-day MA of 69.78, and above the 200-day MA of 69.15, indicating a neutral trend. The MACD of 0.26 indicates Positive momentum. The RSI at 51.66 is Neutral, neither overbought nor oversold. The STOCH value of 42.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PTCT.
PTC Therapeutics Risk Analysis
PTC Therapeutics disclosed 53 risk factors in its most recent earnings report. PTC Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PTC Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $6.21B | 12.56 | 87.36% | ― | 81.26% | 1079.73% | |
56 Neutral | $5.86B | -31.36 | 99.84% | ― | -53.34% | -130.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $5.49B | -8.76 | -30.88% | ― | -89.11% | -37.55% | |
48 Neutral | $7.04B | -6.98 | -32.51% | ― | ― | -71.33% |
* Healthcare Sector Average
PTCT
PTC Therapeutics
70.97
19.28
37.30%
TGTX
TG Therapeutics
40.16
0.32
0.80%
CRSP
Crispr Therapeutics AG
51.84
9.75
23.16%
PCVX
Vaxcyte
47.36
10.16
27.31%
PTC Therapeutics Corporate Events
Executive/Board ChangesShareholder Meetings
PTC Therapeutics Shareholders Back Board, Pay and Auditor
Positive
Jun 5, 2026
PTC Therapeutics reported the results of its June 2, 2026 annual meeting of stockholders, where investors elected four Class I directors, including CEO Matthew B. Klein, M.D., to serve until the 2029 annual meeting or until successors are chosen. ...
Business Operations and StrategyFinancial Disclosures
PTC Therapeutics Lifts 2026 Outlook on Sephience Momentum
Positive
May 7, 2026
On May 7, 2026, PTC Therapeutics reported first-quarter 2026 revenue of $273 million, driven by $226 million in product sales and strong momentum from the global launch of Sephience, which generated $125 million and 36% quarter-over-quarter growth...
Business Operations and StrategyProduct-Related Announcements
PTC Therapeutics Reports Positive 24-Month Votoplam Data
Positive
Apr 28, 2026
On April 28, 2026, PTC Therapeutics reported positive 24‑month interim data from the PIVOT‑HD long‑term extension study of votoplam in Huntington’s disease, showing a dose‑dependent slowing of disease progression in S...
Business Operations and StrategyExecutive/Board Changes
PTC Therapeutics Adds Veteran Banker to Board
Positive
Mar 25, 2026
On March 24, 2026, PTC Therapeutics appointed veteran biotechnology investment banker Jessica Chutter to its board of directors as a Class I director, with her term running until the 2026 annual shareholders’ meeting. Chutter, who recently r...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.